Xeljanz FDA Approval History
Last updated by Judith Stewart, BPharm on Dec 14, 2021.
FDA Approved: Yes (First approved November 6, 2012)
Brand name: Xeljanz
Generic name: tofacitinib
Dosage form: Tablets and Oral Solution
Company: Pfizer Inc.
Treatment for: Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis
Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor used for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis.
Development timeline for Xeljanz
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.